SereNeuro Therapeutics is developing SN101, an iPSC‑derived therapy that delivers mature peripheral nociceptor neurons directly into osteoarthritic joints to modulate pain signaling and support tissue health. The cell‑based product aims to provide non‑opioid, disease‑modifying pain relief, with a GMP‑compliant manufacturing platform for partnership with pharma and biotech developers.
Funding
Funding not disclosed
Founders
Product
Problem
Chronic osteoarthritis and neuropathic pain are often managed with opioid medications, which carry risks of addiction and do not address underlying joint degeneration. Patients lacking effective, non‑addictive treatments experience reduced quality of life and increased healthcare utilization.
Solution
SereNeuro Therapeutics is developing SN101, a first‑in‑class therapy derived from induced pluripotent stem cells (iPSCs) that delivers mature peripheral pain‑sensing neurons (nociceptors) directly to affected joints. By integrating functional nociceptors into the joint environment, SN101 aims to modulate pain signaling at its source while supporting joint tissue preservation. The approach bypasses systemic opioid exposure and targets the biological mechanisms of chronic pain, offering a potential disease‑modifying solution for osteoarthritis patients. Preclinical studies focus on safety, engraftment efficiency, and sustained analgesic effect, positioning SN101 for future clinical translation.
Target Audience
Primary customers are pharmaceutical and biotechnology companies developing advanced pain therapeutics, as well as orthopedic surgeons and rheumatologists seeking non‑opioid treatment options for osteoarthritis patients.
Features
- iPSC‑derived mature peripheral nociceptors engineered for targeted intra‑articular delivery
- Autologous‑compatible cell source reduces immunogenicity risk
- Dual mechanism: analgesic signaling modulation and support of joint tissue health
- Scalable cell manufacturing platform adhering to Good Manufacturing Practice (GMP) standards
- Preclinical validation pipeline including pain behavior assays and joint histopathology